{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,7]],"date-time":"2026-11-07T10:31:56Z","timestamp":1794047516064,"version":"4.8.0"},"reference-count":0,"publisher":"Oxford University Press (OUP)","issue":"4","license":[{"start":{"date-parts":[[2021,10,1]],"date-time":"2021-10-01T00:00:00Z","timestamp":1633046400000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["eje.bioscientifica.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2021,10,1]]},"abstract":"<jats:sec>\n                    <jats:title>Objective<\/jats:title>\n                    <jats:p>To report the final long-term safety and efficacy analyses of patients with acromegaly treated with pegvisomant from the ACROSTUDY.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Design<\/jats:title>\n                    <jats:p>Global (15 countries), multicentre, non-interventional study (2004\u20132017).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>The complete ACROSTUDY cohort comprised patients with acromegaly, who were being treated with pegvisomant (PEGV) prior to the study or at enrolment. The main endpoints were long-term safety (comorbidities, adverse events (AEs), pituitary tumour volumes, liver tests) and efficacy (IGF1 changes).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      Patients (\n                      <jats:italic>n<\/jats:italic>\n                      \u2009=\u20092221) were treated with PEGV for a median of 9.3 years (range, 0\u201320.8 years) and followed up for a median of 7.4 years (range, 0\u201313.9 years). Before PEGV, 96.3% had received other acromegaly treatments (surgery\/radiotherapy\/medications). Before PEGV treatment, 87.2% of patients reported comorbidities. During ACROSTUDY, 5567 AEs were reported in 56.5% of patients and of these 613 were considered treatment-related (in 16.5% of patients) and led to drug withdrawal in 1.3%. Pituitary imaging showed a tumour size increase in 7.1% of patients; the majority (71.1%) reported no changes. Abnormal AST or ALT liver tests occurred in 3.2% of patients. IGF1 normalization rate improved over time, increasing from 11.4% at PEGV start to 53.7% at year 1, and reaching 75.4% at year 10 with the use of \u226530 mg PEGV\/day in an increasing proportion of patients.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>This comprehensive review of the complete cohort in ACROSTUDY confirmed the overall favourable benefit-to-risk profile and high efficacy of PEGV as mono- and combination therapy in patients with an aggressive course\/uncontrolled\/active acromegaly requiring long-term medical therapy for control.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1530\/eje-21-0239","type":"journal-article","created":{"date-parts":[[2021,8,3]],"date-time":"2021-08-03T08:59:21Z","timestamp":1627981161000},"page":"525-538","update-policy":"https:\/\/doi.org\/10.1530\/crossmarkpolicy-7","source":"Crossref","is-referenced-by-count":80,"title":["More than a decade of real-world experience of pegvisomant for acromegaly: ACROSTUDY"],"prefix":"10.1093","volume":"185","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-9284-6289","authenticated-orcid":true,"given":"Maria","family":"Fleseriu","sequence":"first","affiliation":[{"name":"1Pituitary Center Division of Endocrinology, Diabetes, & Clinical Nutrition, Department of Medicine"},{"name":"2Pituitary Center, Department of Neurological Surgery, Oregon Health & Science University, Portland, Oregon, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dagmar","family":"F\u00fchrer-Sakel","sequence":"additional","affiliation":[{"name":"3Department of Endocrinology Diabetology and Metabolism, Endocrine Tumour Center at West German Cancer Center, University Hospital Essen, University of Duisburg-Essen, Essen, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aart J","family":"van der Lely","sequence":"additional","affiliation":[{"name":"4Division of Endocrinology, Department of Internal Medicine, Erasmus Medical Centre, Rotterdam, Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laura","family":"De Marinis","sequence":"additional","affiliation":[{"name":"5Pituitary Unit, Department of Endocrinology, Fondazione A Gemelli, IRCCS, Universit\u00e0 Cattolica del Sacro Cuore, Rome, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8482-6691","authenticated-orcid":true,"given":"Thierry","family":"Brue","sequence":"additional","affiliation":[{"name":"6Assistance Publique-H\u00f4pitaux de Marseille, Hopital de la Conception, and Aix-Marseille Universit\u00e9, Marseille Medical Genetics, Marseille, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joli","family":"van der Lans-Bussemaker","sequence":"additional","affiliation":[{"name":"7Pfizer, Capelle aan den IJssel, Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Judith","family":"Hey-Hadavi","sequence":"additional","affiliation":[{"name":"8Pfizer, New York, New York, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cecilia","family":"Camacho-Hubner","sequence":"additional","affiliation":[{"name":"8Pfizer, New York, New York, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael P","family":"Wajnrajch","sequence":"additional","affiliation":[{"name":"8Pfizer, New York, New York, USA"},{"name":"9Division of Pediatric Endocrinology, Department of Pediatrics, New York University Langone Medical Center, New York, New York, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Srinivas Rao","family":"Valluri","sequence":"additional","affiliation":[{"name":"8Pfizer, New York, New York, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrew Anthony","family":"Palladino","sequence":"additional","affiliation":[{"name":"10Pfizer, Collegeville, Pennsylvania, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roy","family":"Gomez","sequence":"additional","affiliation":[{"name":"11Pfizer, Brussels, Belgium"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roberto","family":"Salvatori","sequence":"additional","affiliation":[{"name":"12Division of Endocrinology and Pituitary Center, Johns Hopkins University School of Medicine, Baltimore, Maryland, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","container-title":["European Journal of Endocrinology"],"original-title":[],"link":[{"URL":"https:\/\/eje.bioscientifica.com\/view\/journals\/eje\/185\/4\/EJE-21-0239.xml","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/eje.bioscientifica.com\/downloadpdf\/journals\/eje\/185\/4\/EJE-21-0239.xml","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,2,14]],"date-time":"2023-02-14T11:16:30Z","timestamp":1676373390000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/ejendo\/article\/185\/4\/525\/6654392"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,10,1]]},"references-count":0,"journal-issue":{"issue":"4"},"URL":"https:\/\/doi.org\/10.1530\/eje-21-0239","relation":{"has-review":[{"id-type":"doi","id":"10.3410\/f.740591190.793589092","asserted-by":"object"}]},"ISSN":["0804-4643","1479-683X"],"issn-type":[{"value":"0804-4643","type":"print"},{"value":"1479-683X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,10,1]]}}}